How would you approach treatment of recurrent cervical cancer in a young patient with ESRD on dialysis?

Community
Company
News
Contact Us
Sign in

Topics: Gynecologic Cancers • Cervical Cancer • Medical Oncology

Originally treated with cis/RT 1.5y ago. Has severe peripheral neuropathy (etiology unknown) and recently underwent palliative bowel resection with colostomy due to bowel perforation (5 weeks ago).

Related Questions

When, if ever, would you consider consolidation treatment with an immune checkpoint inhibitor for the treatment of small cell carcinoma of the cervix following neoadjuvant platinum, resection and radiation, currently without any evidence of disease ?

Will you be changing your management of locally advanced cervical cancer based on the results of the INTERLACE trial presented at ESMO 2023?

How do you treat cervical cancer with an ovarian metastasis?

How do you manage a patient with cervical cancer who has FDG uptake in bilateral ischial tuberosities with lytic areas on CT correlate, and also has a history suspicious for untreated polymyalgia rheumatica with chronic symptoms in the same anatomic locations?

What are your top takeaways in Gynecologic Cancers from ASCO 2023?

Do you recommend progesterone for endometrial protection in a young woman on estrogen replacement therapy for iatrogenic menopause after definitive radiation therapy for locally advanced cervical cancer?

What are magic mouthwash alternatives that you would recommend?

For patients on immune checkpoint inhibitors presenting with chest pain, dyspnea, fatigue, and troponin elevation, would you recommend early initiation of high dose steroids for empiric treatment of ICI myocarditis while pursuing workup with coronary angiogram, echocardiogram, and/or cardiac MRI, or wait until alternative etiologies have been ruled out?

Do you use maintenance bevacizumab in addition to immunotherapy after 1st line chemotherapy + immunotherapy + bevacizumab in metastatic cervical squamous cell carcinoma?

Would you recommend PARP inhibitor maintenance for a patient with HR-proficient ovarian cancer with no targetable mutation, but with a favorable KELIM score and a significant clinical, radiographic, and serological response to platinum-based chemotherapy?